|
|
|
|
|
|
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期- |
A 4 week phase 2a, multicentre, randomised, double-blind, placebo-controlled add-on study into safety, tolerability and efficacy of 200 mg t.i.d. of PL37 in patients with peripheral neuropathic pain of diabetic origin treated with pregabalin or gabapentin.
100 项与 Pharmaleads SA 相关的临床结果
0 项与 Pharmaleads SA 相关的专利(医药)
100 项与 Pharmaleads SA 相关的药物交易
100 项与 Pharmaleads SA 相关的转化医学